December 30, 2009 - FDA Clearance for E Series Monitor Defibrillator with CO Measurement

INVESTOR CONTACT:

A. Ernest Whiton
Chief Financial Officer
ZOLL Medical Corporation
+1 (978) 421-9655

MEDIA CONTACT:

Diane Egan
ZOLL Medical Corporation
+1 (978) 421-9637
degan@zoll.com

ZOLL Receives FDA Clearance to Market E Series Defibrillators with Carbon Monoxide Monitoring

Protects Firefighters and Civilians from a Silent Killer

December 30, 2009CHELMSFORD, MASS.–ZOLL Medical Corporation (Nasdaq GS: ZOLL), a manufacturer of resuscitation devices and related software solutions, has received 510(k) clearance from the U.S. Food and Drug Administration (FDA) for a new model of the ZOLL E Series® Monitor/Defibrillator with carbon monoxide (CO) measurement.  The product is immediately available for shipment.

CO measurement is a breakthrough that helps rescuers noninvasively and immediately diagnose, monitor, and treat patients poisoned by this “silent killer.” CO poisoning can present with flu-like symptoms, but it is also possible to be affected without having any symptoms at all.1 Undetected, untreated episodes can lead to permanent neurological and cardiac damage, and often death.

In firefighters, even mild CO poisoning causes mental confusion, which can put both the exposed rescuer and others on the fire scene at risk.2  Consistent exposure to CO may cause long term heart and brain damage.3  In addition, for both firefighters and civilians, just one severe incident of CO poisoning almost doubles the risk of premature death.4

Now with integrated Masimo® CO-Oximetry® carbon monoxide measurement, the E Series allows rescuers to easily and accurately diagnose CO poisoning with the simple push of a button. Recognition is the key to immediate on-scene treatment. With early detection, treatment for CO poisoning can begin immediately, which significantly reduces immediate and long-term health risks for both firefighters and the civilians whom they serve.

“Integrating CO-Oximetry into the E Series Monitor/Defibrillator adds a critical, life-saving tool for medics to use in emergency situations when every second counts,” said Jonathan A. Rennert, President of ZOLL.  “This new feature will help alleviate some of the long-term health conditions associated with undetected CO poisoning.”

ZOLL’s “Street Smart, Street Tough” E Series was designed by EMS professionals to meet the specific demands and extreme conditions that professional rescuers face every day. It features unique See-Thru CPR®, which filters out CPR artifact, allowing rescuers to see organized rhythms without interrupting chest compressions. Like all other ZOLL defibrillators, the E Series also provides Real CPR Help® which improves CPR quality by providing real-time feedback on the rate and depth of chest compressions. The E Series also offers wireless 12-lead transmission for improved STEMI (ST segment elevation myocardial infarction) management..

About ZOLL Medical Corporation

ZOLL Medical Corporation develops and markets medical devices and software solutions that help advance emergency care and save lives, while increasing clinical and operational efficiencies. With products for defibrillation and monitoring, circulation and CPR feedback, data management, fluid resuscitation, and therapeutic temperature management, ZOLL provides a comprehensive set of technologies which help clinicians, EMS and fire professionals, and lay rescuers treat victims needing resuscitation and critical care.

A NASDAQ Global Select company and a Forbes 100 Most Trustworthy Company for the past three years, ZOLL develops and manufactures its products in the United States, in California, Colorado, Illinois, Massachusetts, Pennsylvania, and Rhode Island. More than 400 direct sales and service representatives, 1,100 business partners, and 200 independent representatives serve our customers in over 140 countries around the globe. For more information, visit www.zoll.com.

Certain statements contained in this press release, including statements regarding the future business of the Company, and other statements contained herein regarding matters that are not historical facts, are “forward-looking” statements (as defined in the Private Securities Litigation Reform Act of 1995). Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from those expressed or implied by such forward-looking statements include, but are not limited to, those factors discussed in the section entitled “Risk Factors” in the Company's Annual  Report on Form 10-K filed with the SEC on December 10, 2009. You should not place undue reliance on the forward looking statements in this press release, and the Company disavows any obligation to update or supplement those statements in the event of any changes in the facts, circumstances, or expectations that underlie those statements.

Copyright © 2009 ZOLL Medical Corporation. All rights reserved. 269 Mill Road, Chelmsford, MA 01824-4105. ZOLL, E Series, Real CPR Help, and See-Thru CPR are registered trademarks of ZOLL Medical Corporation. All product names are the property of their respective owners.

1 Hampson NB et al. American Journal of Emergency Medicine. 2008:26;665-669.
2Jakubowski G FireRescue Magazine. 2004:22(11);52-55.
3Bledsoe BE Journal of Emergency Medical Service. 2007:32;54-59.
4Hampton NB et al. Crit Care Med. 2009:37(6);1941-47.